I would like to welcome you all to Dr. Tran BioSci Advisory. As a medical doctor and market expert, I'm well known in the market and digital media community. For new comers, I wish to share with you my background and missions for this consultancy. In 2013, I founded Retail Investor 360 and Vincata Enterprises LLC to help everyday investors and to assist life science firms gain exposure to the investing community. In 2017, I launched Dr. Tran BioSci Advisory to fulfill a three-prongs mission: to innovate lifesaving medicine for patients, to deliver differentiated market intelligence for investors, and to unlock premium valuations for firms.
Before graduate school, I gained first hand experience in the earliest phase of drug development as a cancer research lab assistant at UNC-Chapel Hill. Thereafter, I dedicated a year to educate general and organic chemistry at UNC-Charlotte as a teaching assistant. The experience of a teacher helped me to elucidate the intricacies of science in simple terms for all readers. In 2007, I earned a master of science degree at the Columbia University in New York, where I focused on research pertaining to human nutrition and medicine. Through the Institute of Human Nutrition, I published as author in the respectable Encyclopedia of Obesity along with the renowned Professor Kathleen Keller. The wisdom learned from top notched faculties at Columbia enabled me to gain invaluable insights into developing therapeutics. In 2013, I received the doctoral degree from East Carolina University. The wisdom of a medical doctor enabled me to be cognizant of prescribing patterns and medicine roles in disease management. Furthermore, it helped me to recognize unfilled markets and innovating therapeutics that are likely to achieve success.
In finance, I've studied extensively from the works of world renown investors, not limited to Phillip Fisher, Benjamin Graham, Warren Buffett, John Templeton, Mohnish Pabrai and Joel Greenblat. Despite my reception toward digital information, I adamantly adhere to the timeless fundamentals of intelligent investing. Leveraging on my diverse background, I pioneered integrated research. This comprehensive style of analytical research enabled me to accurately forecast clinical trials outcomes far in advance of the market. Notable studies include the Flint Trials of Intercept Pharmaceuticals and the Ascend of InterMune Inc. Most firms that I covered in the previous years gained multiple folds for investors either through shares price appreciation or equity acquisition. Key examples are Medivation, Jazz Pharmaceuticals and Exelixis, Inc.
Through my work, I formed meaningful relationships with professional as well as retail investors, KOLs and CEOs. My research intelligence is well-respected by market leaders. I predominantly published long investing theses, as the rewards are most substantial. In the early days of market experimentation, I issued a few short articles. Asides testing the water, I refined my skills in avoiding weak firms and picking winners. Interestingly, my overall short accuracy has been more accurate than long. KOLs who short firms seek my counsel. Rare short theses that I issued have yet to see daylight. Despite that I am bound to make mistakes, I hope to continue a highly accurate track record of data analysis in the future. With much wisdom of a maverick as well as invaluable experience gained in my rookie years, I'm now poised to exclusively focus on publishing long thesis to unlock premium valuations. I welcome partnership and collaboration with other market leaders, investors and companies with similar value. I would like to send my warm regards to all my readers. And I look forward to provide stellar services as well as to learn from you.
Sincerely yours,
Hung V. Tran, M.D., M.S., C.C.M.A.
"Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
To learn how Dr. Tran BioSci can serve your specific needs
Before graduate school, I gained first hand experience in the earliest phase of drug development as a cancer research lab assistant at UNC-Chapel Hill. Thereafter, I dedicated a year to educate general and organic chemistry at UNC-Charlotte as a teaching assistant. The experience of a teacher helped me to elucidate the intricacies of science in simple terms for all readers. In 2007, I earned a master of science degree at the Columbia University in New York, where I focused on research pertaining to human nutrition and medicine. Through the Institute of Human Nutrition, I published as author in the respectable Encyclopedia of Obesity along with the renowned Professor Kathleen Keller. The wisdom learned from top notched faculties at Columbia enabled me to gain invaluable insights into developing therapeutics. In 2013, I received the doctoral degree from East Carolina University. The wisdom of a medical doctor enabled me to be cognizant of prescribing patterns and medicine roles in disease management. Furthermore, it helped me to recognize unfilled markets and innovating therapeutics that are likely to achieve success.
In finance, I've studied extensively from the works of world renown investors, not limited to Phillip Fisher, Benjamin Graham, Warren Buffett, John Templeton, Mohnish Pabrai and Joel Greenblat. Despite my reception toward digital information, I adamantly adhere to the timeless fundamentals of intelligent investing. Leveraging on my diverse background, I pioneered integrated research. This comprehensive style of analytical research enabled me to accurately forecast clinical trials outcomes far in advance of the market. Notable studies include the Flint Trials of Intercept Pharmaceuticals and the Ascend of InterMune Inc. Most firms that I covered in the previous years gained multiple folds for investors either through shares price appreciation or equity acquisition. Key examples are Medivation, Jazz Pharmaceuticals and Exelixis, Inc.
Through my work, I formed meaningful relationships with professional as well as retail investors, KOLs and CEOs. My research intelligence is well-respected by market leaders. I predominantly published long investing theses, as the rewards are most substantial. In the early days of market experimentation, I issued a few short articles. Asides testing the water, I refined my skills in avoiding weak firms and picking winners. Interestingly, my overall short accuracy has been more accurate than long. KOLs who short firms seek my counsel. Rare short theses that I issued have yet to see daylight. Despite that I am bound to make mistakes, I hope to continue a highly accurate track record of data analysis in the future. With much wisdom of a maverick as well as invaluable experience gained in my rookie years, I'm now poised to exclusively focus on publishing long thesis to unlock premium valuations. I welcome partnership and collaboration with other market leaders, investors and companies with similar value. I would like to send my warm regards to all my readers. And I look forward to provide stellar services as well as to learn from you.
Sincerely yours,
Hung V. Tran, M.D., M.S., C.C.M.A.
"Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
To learn how Dr. Tran BioSci can serve your specific needs
